EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Hepatocyte growth factor as indicator for subclinical atherosclerosis

Philip Sommer iD, Michael Schreinlechner iD, Maria Noflatscher, Clarisse Engl, Daniela Lener iD, Markus Theurl iD, Rudolf Kirchmair, Peter Marschang iD

Vasa · 2024

DOI: 10.1024/0301-1526/a001111 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Vasa, 2024. Verfasst von Philip Sommer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III (Cardiology and Angiology), Medical University of Innsbruck, Austria. Hauptthemen laut MEDLINE: Atherosclerosis, Hepatocyte Growth Factor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocyte growth factor (HGF) is a pleiotropic cytokine mainly produced by mesenchymal cells. After endothelial damage by oxidized low-density lipoprotein (LDL), HGF is produced and released into the circulation in response. Due to this mechanism HGF has been proposed as possible clinical biomarker for clinical as well as subclinical atherosclerosis. Patients and methods: The conducted study is an observational, single centre, cohort study, including 171 patients with at least one cardiovascular risk factor or already established cardiovascular disease (CVD). Each patient underwent 3D plaque volumetry of the carotid and femoral arteries as well as physical examination and record of the medical history. Additionally, plasma HGF and further laboratory parameters like high sensitivity C-reactive protein and LDL-cholesterol were determined.

Results

169 patients were available for statistical analysis. In bivariate correlation, HGF showed a highly significant correlation with total plaque volume (TPV, r=0.48; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisHepatocyte Growth FactorHumansCardiovascular DiseasesCohort StudiesPlaque, AtheroscleroticRisk Factors

Stichwörter der Autor:innen

3D ultrasonographyAtherosclerosishepatocyte growth factor

Substanzen

Hepatocyte Growth Factor

Autor:innen und Institutionen

  • Department of Internal Medicine III (Cardiology and Angiology), Medical University of Innsbruck, Austria.
  • Department of Internal Medicine I (Cardiology, Angiology and Pulmology), Klinikum rechts der Isar, Technical University Munich, Germany.
  • Department of Immunology, University of Pittsburgh, The Assembly, Pittsburgh, PA, USA.
  • Department of Internal Medicine, Central Hospital of Bolzano (SADES-ASDAA), Teaching Hospital of Paracelsus Medical University (PMU), Bolzano, Italy.

ORCID-Profile: Philip Sommer, Michael Schreinlechner, Daniela Lener, Markus Theurl, Peter Marschang

Zitieren

APA

Sommer, P., Schreinlechner, M., Noflatscher, M., Engl, C., Lener, D., Theurl, M., Kirchmair, R., & Marschang, P. (2024). Hepatocyte growth factor as indicator for subclinical atherosclerosis. Vasa. https://doi.org/10.1024/0301-1526/a001111

Vancouver

Sommer P, Schreinlechner M, Noflatscher M, Engl C, Lener D, Theurl M, et al. Hepatocyte growth factor as indicator for subclinical atherosclerosis. Vasa. 2024. doi:10.1024/0301-1526/a001111

BibTeX
@article{Sommer2024,
  author = {Sommer, Philip and Schreinlechner, Michael and Noflatscher, Maria and Engl, Clarisse and Lener, Daniela and Theurl, Markus and Kirchmair, Rudolf and Marschang, Peter},
  title = {Hepatocyte growth factor as indicator for subclinical atherosclerosis},
  journal = {Vasa},
  year = {2024},
  doi = {10.1024/0301-1526/a001111}
}
Kostenlos starten →